Search

for
Search:

GlossaryGLP-1 receptor agonists

mimic a hormone to regulate blood sugar and promote fullness

GLP-1 receptor agonists are a class of medications that mimic the action of the glucagon-like peptide-1 (GLP-1) hormone, which helps regulate blood sugar levels by enhancing insulin secretion and inhibiting glucagon release. They are commonly used in the treatment of type 2 diabetes and can also promote weight loss by slowing gastric emptying and increasing feelings of fullness.

Related Terms

Sort by

Research

30 / 322 results

research GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

59 citations , August 2021 in “Frontiers in Endocrinology”

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

research Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons

1 citations , September 2025 in “Dermatology and Therapy”

GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.

Associations Between GLP-1 Receptor Agonists and Alopecia: A Multi-Center Retrospective Analysis and Public Interest Trends

research Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends

October 2025 in “JEADV Clinical Practice”

GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.

Alopecia as an Emerging Adverse Effect Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss: A Scoping Review

research Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review

August 2025 in “Cureus”

GLP-1 receptor agonists for weight loss may cause hair loss, especially in women.

research Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review

February 2025 in “Skin Appendage Disorders”

GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.

research Prevalence and Predictors of Hair Shedding among GLP-1 Receptor Agonist Users: A Cross-Sectional Study from Saudi Arabia

January 2026 in “Skin Appendage Disorders”

Hair shedding is common in GLP-1 users, affecting treatment adherence.

research The Impact of GLP-1 Receptor Agonists on Hair: Beneficial Effects or Adverse Outcomes?

April 2026 in “American Journal of Clinical Dermatology”

research Increased risk of hair loss with GLP-1 receptor agonists: A real-world multicenter TrinetX cohort study

February 2026 in “JAAD International”

research Effects of GLP ‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review

October 2025 in “International Journal of Dermatology”

GLP-1 receptor agonists may cause hair loss, but regrowth is rare.

Increased Incidence and Risk of Hair Loss with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Multicenter Cohort Study

research Increased Incidence and Risk of Hair Loss with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Multicentre Cohort Study

October 2025 in “EMJ Dermatology”

GLP-1RA therapy may increase the risk of hair loss.

From Evidence to Practice: Insights from the Multidisciplinary Team on the Optimal Integration of GLP-1 Receptor Agonists in Obesity Management Services

research “From evidence to practice” – Insights from the multidisciplinary team on the optimal integration of GLP‐1 receptor agonists in obesity management services

August 2024 in “Nutrition Bulletin”

GLP-1 receptor agonists help with weight loss but need to be combined with other treatments for best results.

Use of Glucagon-Like Peptide-1 Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review

research Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review

September 2025 in “Cureus”

GLP-1 agonists may help treat certain skin conditions.

research Risk of Alopecia Areata with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

February 2025 in “medRxiv (Cold Spring Harbor Laboratory)”

GLP-1 agonists may increase the risk of hair loss.

research Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review

5 citations , August 2024 in “Cureus”

GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.

GLP-1 Receptor Agonists and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions

research GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions

June 2025

GLP-1 receptor agonists can cause skin and hair issues due to rapid weight loss, but these can be managed with proper care and treatments.

research Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications

January 2025 in “Journal of the European Academy of Dermatology and Venereology”

Newer GLP-1 drugs like semaglutide may cause hair loss.

research Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin

37 citations , March 2006 in “Regulatory Peptides”

Mice skin has components that could help with hair growth and might be used for diabetes treatment.

Risk of Suicide, Hair Loss, and Aspiration with Glucagon-Like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS Database

research Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database

November 2024 in “Circulation”

GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.

research The Impact of Glucagon-like Peptide-1 Receptor Agonists on Erectile Function: Friend or Foe?

4 citations , September 2025 in “Biomolecules”

The effect of GLP-1 RAs on erectile function is unclear and needs more research.

Metabolic Syndrome – A New Definition and Management Guidelines: A Joint Position Paper by Various Polish Medical Societies

research Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons

20 citations , August 2022 in “Archives of Medical Science”

The Polish medical societies have redefined metabolic syndrome and recommend lifestyle changes, certain medications, and possibly bariatric surgery for treatment. They also discuss managing related health conditions.

research Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome

4 citations , January 2019 in “Therapeutic Advances in Endocrinology and Metabolism”

Medications for PCOS don't seem to raise heart disease risk.

research Alopecia and Semaglutide: Connecting the Dots for Patient Safety

4 citations , March 2025 in “Journal of Cosmetic Dermatology”

Semaglutide may cause hair loss, but more research is needed to confirm this.

research Women with PCOS have a heightened risk of cardiometabolic and cardiovascular diseases: statement from the Experts Group on Inositol in Basic and Clinical Research and PCOS (EGOI-PCOS) and Italian Association of Hospital Cardiologists (ANMCO)

3 citations , September 2025 in “Frontiers in Cardiovascular Medicine”

Women with PCOS have a higher risk of heart disease.

research Non-Hormonal Treatment Options for Regulation of Menstrual Cycle in Adolescents with PCOS

2 citations , December 2022 in “Journal of Clinical Medicine”

Medications for glucose metabolism and weight control, combined therapy options, and herbal medicines may help regulate menstrual cycle in adolescents with PCOS.

research Impact of Reducing Obesity in PCOS: Methods and Treatment Outcomes

1 citations , October 2025 in “Journal of Personalized Medicine”

Weight loss improves PCOS symptoms and overall health.

research Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review

1 citations , August 2025

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.